Noopur Raje, MD
Denosumab (Xgeva) was noninferior to zoledronic acid (Zometa) in preventing skeletal-related event (SREs) in patients with newly diagnosed multiple myeloma, results recently published in The Lancet Oncology
In the international, double-blind randomized phase III 482 Study, the RANK ligand inhibitor denosumab was equal to zoledronic acid in delaying time to first SRE (hazard ratio [HR], 0.98; 95% CI, 0.85-1.14; P
for noninferiority = .010). Based on these findings, the FDA approved denosumab in January 2018 for the prevention of SREs in patients with multiple myeloma.
... to read the full story